Skip to Content

Generic Fanapt Availability

Fanapt is a brand name of iloperidone, approved by the FDA in the following formulation(s):

FANAPT (iloperidone - tablet;oral)

  • Manufacturer: VANDA PHARMS INC
    Approval date: May 6, 2009
    Strength(s): 1MG [RLD], 2MG, 4MG, 6MG, 8MG, 10MG, 12MG

Has a generic version of Fanapt been approved?

No. There is currently no therapeutically equivalent version of Fanapt available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fanapt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for the administration of iloperidone
    Patent 8,586,610
    Issued: November 19, 2013
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Patent expiration dates:
    • November 2, 2027
      ✓ 
      Patent use: METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
  • Prediction of QT prolongation based on SNP genotype
    Patent 8,652,776
    Issued: February 18, 2014
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Patent expiration dates:
    • August 31, 2030
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Method of treatment based on polymorphisms of the KCNQ1 gene
    Patent 8,999,638
    Issued: April 7, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Patent expiration dates:
    • October 28, 2030
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Method of predicting a predisposition to QT prolongation
    Patent 9,072,742
    Issued: July 7, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Patent expiration dates:
    • January 16, 2031
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Method of predicting a predisposition to QT prolongation
    Patent 9,074,254
    Issued: July 7, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Patent expiration dates:
    • December 28, 2031
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Method of predicting a predisposition to QT prolongation
    Patent 9,074,255
    Issued: July 7, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Patent expiration dates:
    • December 17, 2030
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Method of predicting a predisposition to QT prolongation
    Patent 9,074,256
    Issued: July 7, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Patent expiration dates:
    • February 10, 2031
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Methods for the administration of iloperidone
    Patent 9,138,432
    Issued: September 22, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The present invention relates to methods for treating a patient with iloperidone or a metabolite thereof, which patient is also being treated with fluoxetine, and lowering risk for QT prolongation.
    Patent expiration dates:
    • September 30, 2025
      ✓ 
      Patent use: METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
  • Method of treatment based on polymorphisms of the KCNQ1 gene
    Patent 9,157,121
    Issued: October 13, 2015
    Assignee(s): Vanda Pharmaceuticals, Inc.
    The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
    Patent expiration dates:
    • April 5, 2030
      ✓ 
      Patent use: DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
  • Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics
    Patent RE39198
    Issued: July 18, 2006
    Inventor(s): Strupczewski; Joseph T. & Helsley; Grover C. & Chiang; Yulin & Bordeau; Kenneth J. & Glamkowski; Edward J.
    Assignee(s): Aventis Pharmaceuticals Inc.
    Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    Patent expiration dates:
    • November 15, 2016
      ✓ 
      Patent use: INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 26, 2019 - INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide